The PPARγ agonist rosiglitazone increased micro RNA miR-15a expression which inhibited angiopoietin-1, resulting in decreased angiogenesis, MSC expansion, and tumor growth in vivo [67]. This evidence concerns the gene PPARG and neoplasm.